Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids

International Journal of Cardiology

Volumn 168, Issue 4, 2013, Pages 4085-4092

  Nguyen, T Dung ^a   Shingu, Yasushige ^b   Amorim, Paulo A ^b   Schwarzer, Michael ^a   Doenst, Torsten ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cardiac function; Cardiac glucose metabolism; Exendin 4; Glucagon like peptide 1

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; EXENDIN 4; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; OLEIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA FLOW; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE METABOLISM; HEART OUTPUT; HEART PERFORMANCE; HEART RATE; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; DRUG EFFECTS; HEART; HEART CONTRACTION; METABOLISM; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; FATTY ACIDS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HEART; MALE; MYOCARDIAL CONTRACTION; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84886294048     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.07.018     Document Type: Article

References (41)

1. R.M. Elliott, L.M. Morgan, J.A. Tredger, S. Deacon, J. Wright, and V. Marks Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns J Endocrinol 138 1993 159 166
2. X. Fu-Cheng, Y. Anini, J. Chariot, T. Voisin, J.P. Galmiche, and C. Roze Peptide YY release after intraduodenal, intraileal, and intracolonic administration of nutrients in rats Pflugers Arch 431 1995 66 75
3. C.F. Deacon, A.H. Johnsen, and J.J. Holst Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J Clin Endocrinol Metab 80 1995 952 957
4. R. Goke, H.C. Fehmann, and T. Linn Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells J Biol Chem 268 1993 19650 19655
5. D.J. Drucker The biology of incretin hormones Cell Metab 3 2006 153 165
6. J.J. Holst The physiology of glucagon-like peptide 1 Physiol Rev 87 2007 1409 1439
7. D.M. Nathan, J.B. Buse, and M.B. Davidson Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
8. A.J. Garber Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability Diabetes Care 34 Suppl. 2 2011 S279 S284
9. K. Raun, P. von Voss, C.F. Gotfredsen, V. Golozoubova, B. Rolin, and L.B. Knudsen Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not Diabetes 56 2007 8 15
10. A. Astrup, S. Rossner, and L. Van Gaal Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 374 2009 1606 1616
11. C.M. Mack, C.X. Moore, and C.M. Jodka Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures Int J Obes (Lond) 30 2006 1332 1340
12. R.A. DeFronzo, R.E. Ratner, J. Han, D.D. Kim, M.S. Fineman, and A.D. Baron Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 28 2005 1092 1100
13. T. Zhao, P. Parikh, and S. Bhashyam Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts J Pharmacol Exp Ther 317 2006 1106 1113
14. W.C. Stanley, F.A. Recchia, and G.D. Lopaschuk Myocardial substrate metabolism in the normal and failing heart Physiol Rev 85 2005 1093 1129
15. J.A. Wisneski, E.W. Gertz, R.A. Neese, and M. Mayr Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans J Clin Invest 79 1987 359 366
16. T.R. Koves, J.R. Ussher, and R.C. Noland Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance Cell Metab 7 2008 45 56
17. T. Doenst, Q. Han, G.W. Goodwin, P.H. Guthrie, and H. Taegtmeyer Insulin does not change the intracellular distribution of hexokinase in rat heart Am J Physiol 275 1998 E558 E567
18. P.A. Amorim, T.D. Nguyen, and Y. Shingu Myocardial infarction in rats causes partial impairment in insulin response associated with reduced fatty acid oxidation and mitochondrial gene expression J Thorac Cardiovasc Surg 140 2010 1160 1167
19. T. Doenst, R.T. Richwine, M.S. Bray, G.W. Goodwin, O.H. Frazier, and H. Taegtmeyer Insulin improves functional and metabolic recovery of reperfused working rat heart Ann Thorac Surg 67 1999 1682 1688
20. M.G. Vila Petroff, J.M. Egan, X. Wang, and S.J. Sollott Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes Circ Res 89 2001 445 452
21. I. Szokodi, P. Kinnunen, P. Tavi, M. Weckstrom, M. Toth, and H. Ruskoaho Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide Circulation 97 1998 1062 1070
22. J. Shan, A. Kushnir, and M.J. Betzenhauser Phosphorylation of the ryanodine receptor mediates the cardiac fight or flight response in mice J Clin Invest 120 2010 4388 4398
23. L. Hue, and H. Taegtmeyer The Randle cycle revisited: a new head for an old hat Am J Physiol Endocrinol Metab 297 2009 E578 E591
24. M. Kim, M.J. Platt, and T. Shibasaki GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure Nat Med 19 2013 567 575
25. W. Gu, D.J. Lloyd, and N. Chinookswong Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice J Pharmacol Exp Ther 338 2011 70 81
26. L.A. Nikolaidis, D. Elahi, and T. Hentosz Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy Circulation 110 2004 955 961
27. I. Poornima, S.B. Brown, S. Bhashyam, P. Parikh, H. Bolukoglu, and R.P. Shannon Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat Circ Heart Fail 1 2008 153 160
28. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
29. H. Yamamoto, C.E. Lee, and J.N. Marcus Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons J Clin Invest 110 2002 43 52
30. K.J. Griffioen, R. Wan, and E. Okun GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons Cardiovasc Res 89 2011 72 78
31. I. Idris, D. Patiag, S. Gray, and R. Donnelly Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1 Biochem Pharmacol 63 2002 993 996
32. C. Zechner, F. Beyersdorf, and T. Doenst The role of calcium in the regulation of glucose uptake in isolated working rat heart Mol Cell Biochem 232 2002 75 80
33. H. Yang, J.M. Egan, and Y. Wang GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor Am J Physiol 275 1998 C675 C683
34. M.A. Luque, N. Gonzalez, and L. Marquez Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes J Endocrinol 173 2002 465 473
35. N. Gonzalez, A. Acitores, V. Sancho, I. Valverde, and M.L. Villanueva-Penacarrillo Effect of GLP-1 on glucose transport and its cell signalling in human myocytes Regul Pept 126 2005 203 211
36. D. Dardevet, M.C. Moore, and C.A. DiCostanzo Insulin secretion- independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors Am J Physiol Gastrointest Liver Physiol 289 2005 G806 G814
37. S. Ben-Shlomo, I. Zvibel, and M. Shnell Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase J Hepatol 54 2011 1214 1223
38. P.F. Blackmore, S. Mojsov, J.H. Exton, and J.F. Habener Absence of insulinotropic glucagon-like peptide-I(7-37) receptors on isolated rat liver hepatocytes FEBS Lett 283 1991 7 10
39. T. Doenst, G. Pytel, and A. Schrepper Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload Cardiovasc Res 86 2010 461 470
40. A.B. Stein, S. Tiwari, and P. Thomas Effects of anesthesia on echocardiographic assessment of left ventricular structure and function in rats Basic Res Cardiol 102 2007 28 41
41. B.P. Cummings, K.L. Stanhope, and J.L. Graham Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats Diabetes 59 2010 2653 2661